EYPT News and Press, EyePoint Pharmaceuticals Inc. From 02/24/22

WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call an...

EyePoint Pharmaceuticals (NASDAQ:EYPT) announces eight-month interim data from the DAVIO Phase 1 clinical trial of EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD). The data will be presented at the  Angiogenesis, Exudation, and ...

EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD - Continued positive efficacy and durability with stable visual acuity (VA) and optical coherence tomog...

– Updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD continue to show positive safety and efficacy results out to eight months. Further results to be presented at the February Angiogenesis 2022 virtual meeting – – Phase 2 study for EYP-1901 in we...

WATERTOWN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment of Michael C...

Founded by Renowned Experts in Ophthalmology and Immunology Launches with $10.5 million Series A Financing Led by Safar Partners to Advance Disease-Modifying Therapy for Ocular Surface Disease into the Clinic BOSTON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aramis Biosciences, In...

WATERTOWN, Mass. and NASHVILLE, Tenn. and CARLSBAD, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, an...

WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of the previousl...

Shares of specialty healthcare company EyePoint Pharmaceuticals (NASDAQ: EYPT) zoomed into the stratosphere on Wednesday. Investors were obviously very pleased with the company's pricing of an upcoming share-and-warrant issue, expressing their delight by pushing the stock up a whopp...

Shares of Eyepoint Pharma (EYPT +27.0%) have soared today even as the company late last night priced a $100M public offering of 4M shares. Trading in the company today is much higher than usual. As of 1142a ET, ~7.8M shares had traded hands. Average daily volumne is 413,290. Shares slumped wh...